gout
GOUT
Gout is a condition that resulted from deposition of monosodium urate crystals in various tissues (eg joints, connective tissue, kidney).
The patient experiences acute and chronic arthritis, soft tissue inflammation, tophus formation, gouty nephropathy and nephrolithiasis.
Primary hyperuricemia is called when uric acid saturation arises without coexisting diseases or drugs that alter uric acid production and excretion.
While in secondary hyperuricemia there is an excessive uric acid production or diminished renal clearance that occurs as a result of a disease, drug, dietary product or toxin.
Drug Information

Indication: Acute & chronic treatment of signs & symptoms of osteoarthritis (OA) & RA; ankylosing spondylitis ...

Indication: Management of acute pain in adults & treatment of primary dysmenorrhea. Relief of acute & chronic pain...

Indication: Chronic hyperuricaemia in conditions where urate deposition has already occurred (including a history, or pres...

Dosage: OA 7.5 mg daily, may be increased to 15 mg daily. RA Initially 15 mg daily, may be reduced to 7.5 mg daily. An

Indication: Clinical manifestations of urate/uric acid deposition. Management of 2, 8-dihydroxyadenine nephroliths & r...

Indication: Symptomatic treatment of OA (arthrosis, degenerative joint disease), RA & ankylosing spondylitis.

Indication: Inflammatory & degenerative forms of rheumatism: RA, juvenile RA, ankylosing spondylitis, OA & spondyl...

Indication: Relief of fever associated w/ cold & flu, pain eg, teething, toothache, earache, sore throat, headache, mi...

Indication: Acute & chronic rheumatic fever, RA, bronchial asthma, myositis, dermatitis.

Indication: Symptomatic relief of OA, RA & ankylosing spondylitis eg, swelling, stiffness & joint pain.

1  /  11
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Rheumatology digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Jairia Dela Cruz, 18 Dec 2018
The use of ixekizumab to selectively target interleukin-17A (IL-17A) in disease-modifying antirheumatic drug-naïve patients with ankylosing spondylitis yields improvements in disease activity, health-related quality of life, day-to-day physical activity, and bone marrow oedema of the spine and sacroiliac joint, according to the results of the phase III COAST-V study.
10 Jan 2019
Only a few sonographic enthesitis scoring instruments developed for spondyloarthritis (SpA) have been validated in psoriatic arthritis (PsA), and none of them passed the Outcome Measures in Rheumatology (OMERACT) filter in patients with PsA, according to a systematic review.